The results of clinical trials evaluating GLP-1 analogs for the treatment of NAFLD are expected in the near future, and the feasibility of using oral drugs, in addition to injectable drugs, is also being evaluated. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.